Survey reveals 4 out of every 10 women reported that menopause symptoms have interfered with their work performance or productivity at least on a weekly basis IRVING, Texas --(BUSINESS WIRE)--Jun. 6, 2022-- Biote , a leading hormone optimization company, today publicly released findings of a 2022

Business combination with Haymaker Acquisition Corp. III complete biote Corp.’s common stock will trade on the Nasdaq Stock Exchange under ticker symbol “BTMD” IRVING, Texas --(BUSINESS WIRE)--May 26, 2022-- biote Corp., (Nasdaq: BTMD) (“Biote” or the “Company”), a high growth, differentiated

NEW YORK, May 24, 2022 (GLOBE NEWSWIRE)  — Haymaker Acquisition Corp. III (Nasdaq: HYAC) (“Haymaker” or the “Company”), a publicly traded special purpose acquisition company, today announced that its stockholders voted to approve the previously announced business combination (the “Business

NEW YORK, May 17, 2022 (GLOBE NEWSWIRE)  — Haymaker Acquisition Corp. III (Nasdaq: HYAC) (“Haymaker” or the “Company”), a publicly traded special purpose acquisition company, reminds its shareholders to vote in favor of the proposed business combination with BioTE Holdings, LLC (“Biote”) and the

Company accelerates expansion and reiterates 2022 guidance Net sales of $37 million in the quarter, an 18% increase year-over-year from the first quarter of 2021. First quarter procedural revenue grew at 21.2% year-over-year. Adjusted EBITDA of $12 million, a 20% increase year-over-year.1 The

Record net sales of $139.4 million for the full year, a 20% increase year-over-year. Record net sales of $37.5 million in the fourth quarter, a 22% increase period-over-period. EBITDA of $36 million, a 9% increase year-over-year. 1 In December 2021, Biote entered into a business combination

Biote is a high-growth medical practice-building company operating within the multi-billion dollar hormone optimization space. Biote-certified practitioners provide personalized therapies to their patients who experience hormone imbalances. Biote is an established company with projected revenue of

IRVING, Texas –BioTE Holdings, LLC (“Biote”), a high-growth medical practice-building company operating within the multi-billion dollar hormone optimization space, today announced that its management team will be participating virtually in the ICR Conference 2022.  Terry Weber, Biote’s Chief

RANKING PRESENTED BY THE WOMEN PRESIDENTS’ ORGANIZATION & JPMORGAN CHASE COMMERCIAL BANKING Irving, Texas – October 15, 2021 – Biote has been announced as one of the 50 Fastest-Growing Women-Owned/Led Companies in the 14 th  annual ranking compiled by The  Women Presidents’ Organization  (WPO) in

BIOTE ANNOUNCED THE APPOINTMENTS OF DR. MARK CONE AND DANA JACOBY TO THE COMPANY’S BOARD OF DIRECTORS. CONE AND JACOBY BRING SIX DECADES OF COMBINED EXPERIENCE IN HEALTHCARE PRACTICE AND BUSINESS LEADERSHIP TO THE COMPANY’S BOARD. IRVING, Texas–( BUSINESS WIRE )– Biote Medical , a hormone